Literature DB >> 22692032

Diffusion-weighted MR imaging for the regional characterization of liver tumors.

Mathilde Wagner1, Sabrina Doblas, Jean-Luc Daire, Valérie Paradis, Nathalie Haddad, Helena Leitão, Philippe Garteiser, Valérie Vilgrain, Ralph Sinkus, Bernard E Van Beers.   

Abstract

PURPOSE: To determine if diffusion-weighted (DW) magnetic resonance (MR) imaging with measurements of the apparent diffusion coefficient (ADC), pure diffusion coefficient, perfusion-related diffusion coefficient, and perfusion fraction can be used to differentiate between viable tumor and fibrous and necrotic regions within malignant liver tumors.
MATERIAL AND METHODS: The prospective study was approved by the institutional review board, and informed consent was obtained from all patients. Forty-eight patients with 51 malignant tumors were assessed. MR images of the liver were obtained by using DW imaging with 11 b factors (0-500 sec/mm(2)) and gadolinium-enhanced three-dimensional gradient-echo T1-weighted imaging. Tumors were segmented into viable tumor and fibrous and necrotic regions according to the enhancement pattern after injection of a nonspecific gadolinium chelate and, in surgically removed lesions, results of histopathologic correlation. The ADC, pure diffusion coefficient, perfusion-related diffusion coefficient, and perfusion fraction were calculated, and values were compared between viable tumor and fibrous and necrotic regions with the Kruskal-Wallis test followed by the Dunn multiple comparison test.
RESULTS: The pure diffusion coefficient differed significantly between regions of viable tumor tissue and fibrosis (1.16 × 10(-3) mm(2)/sec ± 0.29 and 1.48 × 10(-3) mm(2)/sec ± 0.31, respectively; P = .016) and between regions of viable tumor tissue and necrosis (1.70 × 10(-3) mm(2)/sec ± 0.49, P = .002). There was a significantly lower perfusion fraction in necrotic regions (14% ± 6) than in viable tumor regions (21% ± 8, P = .005), but the perfusion fraction of the fibrous regions (21% ± 7) did not differ significantly from that of the other two regions. ADCs and perfusion-related diffusion coefficients did not differ significantly among the three regions.
CONCLUSION: Results of this study show that viable tumor regions in malignant liver tumors can be differentiated from fibrous and necrotic regions with use of the pure diffusion coefficient but not with the other diffusion parameters.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22692032     DOI: 10.1148/radiol.12111530

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  31 in total

1.  Assessment of the residual tumour of colorectal liver metastases after chemotherapy: diffusion-weighted MR magnetic resonance imaging in the peripheral and entire tumour.

Authors:  Mathilde Wagner; Maxime Ronot; Sabrina Doblas; Céline Giraudeau; Bernard Van Beers; Jacques Belghiti; Valérie Paradis; Valérie Vilgrain
Journal:  Eur Radiol       Date:  2015-05-02       Impact factor: 5.315

2.  Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.

Authors:  Julius Chapiro; Laura D Wood; MingDe Lin; Rafael Duran; Toby Cornish; David Lesage; Vivek Charu; Rüdiger Schernthaner; Zhijun Wang; Vania Tacher; Lynn Jeanette Savic; Ihab R Kamel; Jean-François Geschwind
Journal:  Radiology       Date:  2014-07-15       Impact factor: 11.105

3.  Development of a diffusion-weighted MRI protocol for multicentre abdominal imaging and evaluation of the effects of fasting on measurement of apparent diffusion coefficients (ADCs) in healthy liver.

Authors:  J M Winfield; M-V Papoutsaki; H Ragheb; D M Morris; A Heerschap; E G W ter Voert; J P A Kuijer; I C Pieters; N H M Douglas; M Orton; N M de Souza
Journal:  Br J Radiol       Date:  2015-03-19       Impact factor: 3.039

4.  Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.

Authors:  Julius Chapiro; Rafael Duran; MingDe Lin; Rüdiger Schernthaner; David Lesage; Zhijun Wang; Lynn Jeanette Savic; Jean-François Geschwind
Journal:  Eur Radiol       Date:  2015-01-31       Impact factor: 5.315

5.  Intravoxel incoherent motion: application in differentiation of hepatocellular carcinoma and focal nodular hyperplasia.

Authors:  Ma Luo; Ling Zhang; Xin Hua Jiang; Wei Dong Zhang
Journal:  Diagn Interv Radiol       Date:  2017 Jul-Aug       Impact factor: 2.630

6.  Accurate IVIM model-based liver lesion characterisation can be achieved with only three b-value DWI.

Authors:  P Mürtz; A M Sprinkart; M Reick; C C Pieper; A-H Schievelkamp; R König; H H Schild; W A Willinek; G M Kukuk
Journal:  Eur Radiol       Date:  2018-04-18       Impact factor: 5.315

7.  Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.

Authors:  Julius Chapiro; Rafael Duran; MingDe Lin; Rüdiger E Schernthaner; Zhijun Wang; Boris Gorodetski; Jean-François Geschwind
Journal:  Radiology       Date:  2014-12-19       Impact factor: 11.105

Review 8.  Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI.

Authors:  Julius Chapiro; MingDe Lin; Rafael Duran; Rüdiger E Schernthaner; Jean-François Geschwind
Journal:  Expert Rev Anticancer Ther       Date:  2014-11-05       Impact factor: 4.512

9.  Error model for reduction of cardiac and respiratory motion effects in quantitative liver DW-MRI.

Authors:  Paul Murphy; Tanya Wolfson; Anthony Gamst; Claude Sirlin; Mark Bydder
Journal:  Magn Reson Med       Date:  2012-12-27       Impact factor: 4.668

10.  Scan time minimization in hepatic diffusion-weighted imaging: evaluation of the simultaneous multislice acceleration technique with different acceleration factors and gradient preparation schemes.

Authors:  Jana Taron; Petros Martirosian; Nina F Schwenzer; Michael Erb; Thomas Kuestner; Jakob Weiß; Ahmed Othman; Mike Notohamiprodjo; Konstantin Nikolaou; Christina Schraml
Journal:  MAGMA       Date:  2016-04-02       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.